Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications ... suggesting a potential impact on the neural mechanisms associated with addiction[1][2]. This aligns with findings ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut that plays a crucial role in regulating metabolism, particularly in glucose homeostasis and appetite control. It is secreted by ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Authors say large, multisite study should provide reassurance for short-term risk. (HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...